MediGene and Teva sign agreement to commercialize Veregen(TM) in Israel
(Thomson Reuters ONE) -
MediGene AG / MediGene and Teva sign agreement to commercialize Veregen(TM) in Israel processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich,February 22, 2010. The biotech company MediGene AG
(Frankfurt, Prime Standard, TecDAX) has signed a license and supply agreement
with Teva Pharmaceutical Industries Ltd. for the supply and commercialization of
Veregen(TM) in Israel. Teva will also be responsible for registering the product
in Israel, and upon successful completion of the regulatory procedures, MediGene
is entitled to a milestone payment. In addition, MediGene will receive royalties
on future sales of the product. Veregen(TM), for the treatment of genital warts,
is MediGene's first internally developed drug. Veregen(TM) is already available
on the US market and has obtained marketing authorization in Germany.
Dr. Frank Mathias, Chief Executive Officer of MediGene AG, commented: "Following
our European commercialization agreements in Germany, Spain, Portugal, Austria,
and Switzerland, we have now concluded our first partnership for the
commercialization of Veregen(TM) outside Europe and the US. We are particularly
proud to have secured Teva, one of the world's top 20 pharmaceutical companies,
for the distribution of Veregen(TM)."
Veregen(TM): Veregen(TM) (previously Polyphenon E(TM) Ointment) for the
treatment of genital warts contains a concentrate of catechins with a defined
composition, extracted from green tea leaves. MediGene acquired the basic rights
to the active substance in Veregen(TM) from the Canadian company Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
preclinical and clinical development, as well as for the successful
accomplishment of approval procedures for the USA and a number of European
countries. The patent protection was also further upgraded by a number of
proprietary inventions. In the USA the drug has been available since February
2009 and is distributed by MediGene's marketing partner Nycomed US, Inc.
German marketing authorization for Veregen(TM) was granted in September 2009.
Formal issue of marketing authorizations in Austria and Spain is expected during
the next few months, since the clinical data relevant for approval were assessed
positively by the regulatory authorities in these countries. Market launch in
Germany is scheduled for March 2010.
In 2009 MediGene concluded a license and supply agreement with Solvay
Arzneimittel GmbH for Germany, Austria, and Spain. The Spanish pharmaceutical
company Juste S.A.Q.F. will distribute Veregen(TM) in Spain and Portugal.
MediGene is planning to apply for marketing authorization in further European
countries, and intends to conclude additional marketing agreements for countries
in and outside Europe.
Information on Teva Pharmaceutical Industries Ltd. are available on
www.tevapharm.com
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(®) and Veregen(TM) are registered trademarks of MediGene AG. Polyphenon
E(TM) is a registered trademark of Mitsui Norin Co., Ltd. These trademarks may
be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax)
biotechnology company located in Martinsried/Munich, Germany, with subsidiaries
in Oxford, UK and San Diego, USA. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has
several drug candidates in clinical development and possesses innovative
platform technologies. MediGene focuses on clinical research and development of
novel drugs with focus on oncology.
Contact MediGene AG
Email: investor(at)medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
[HUG#1386902]
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903 ;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 12788
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene and Teva sign agreement to commercialize Veregen(TM) in Israel"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
